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Poster Session I S27524 months after transplantation and was lower during the first 120
days in the CD34 group than in the PBSC group (p\0.1, with p
\0.01 on day 40). This difference was more significant after exclud-
ing from the CD34 group patients who had received pre-emptive
DLI (p\0.05, with p\0.01 on days 40 and 60). T-cell repertoire di-
versity was similar in both groups on days 100 and 365 post-PBSCT
(with a median total number for the 24 BV families of 218 bands in
both groups on day 100 post-PBSCT and 223.5 and 236 bands for
the CD34 and PBSC groups respectively on day 365 (p 5 0.67)).
Conclusion: This study suggests that the T-cell depletion of the
graft induced a delayed immune reconstitution for naive CD4+ T
cells after allogeneic PBSCT with high dose conditioning.
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KINETICS OF IL-7 AND IL-15 LEVELS AFTER ALLOGENEIC PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION (ALLO-PBSCT) FOLLOWING
HIGH-DOSE OR NONMYELOABLATIVE CONDITIONING
De Bock, M., Fillet, M., Merville, M.-P., Gothot, A., Beguin, Y.,
Baron, F. University of Liege, Belgium
Background: Successful allo-PBSCT depends on the recovery of an
adequate immune system, allowing not only to prevent lethal infec-
tions but also to induce immune-mediated graft-versus-tumor ef-
fects. Previous studies have demonstrated that immune recovery
depends mainly on homeostatic peripheral expansion (HPE) of do-
nor T cells contained in the graft the first 3-6 mo. following allo-
PBSCT. IL-7 and IL-15 are the main driving forces of HPE, and
are secreted in response to lymphodepletion. While high-dose con-
ditioning regimens induce generally a profound lymphodepletion,
progressive replacement of host-derived by donor-derived T cells
is the rule after nonmyeloablative conditioning.
Patients and Methods: Data from 106 pts given allo-PBSCT after
high-dose (n 5 36) or low-dose TBI based nonmyeloablative (n 5
70) conditioning were analyzed. Among patients given high-dose
conditioning, 26 patients were given unmanipulated PBSC with
(n 5 24) or without (n 5 2) added ATG and 10 patients received
CD34-selected PBSC.No patient in the nonmyeloablative group re-
ceived ATG orCD-34 selected PBSC. IL-7 plasma and IL-15 serum
levels were measured with a commercial ELISA (R&D Systems,
Minneapolis, MN, USA). Lymphocyte subset counts were analyzed
by flow cytometry.
Results: CD4+ T cell and naive CD4+ T cell counts were lower
(P\0.001) on days 28, 40, 60, 80, 100 and 180 in pts given grafts after
high-dose than in those given nonmyeloablative conditioning. IL-7
levels were higher in pts given high-dose than in those given non-
myeloablative conditioning on days 7, 14, 28, 40, 60, 80 and 100 after
transplantation (p\0.01). Day 28 IL-7 levels were highly correlated
(r\-0.52, P\0.0001) with day 28 counts of T cells, CD4+ T cells,
CD8+ T cells, and naive CD4+ T cells but not with day 28 counts
of NK cells. IL-15 levels were higher in patients given high-dose
than in those given non-myeloablative conditioning on days 7
(p\0.01), 14 (p\0.01), and 28 (p 5 0.055) after transplantation.
There was a correlation between IL-15 levels and day 28 counts of
T cells (r 5 -0.30, P 5 0.002) and NK cells (r 5 -0.38, P 5 0.001).
Conclusions: Our data suggest that the physiology of immune re-
covery and particularly of HPE is significantly different in pts given
high-dose than in those given nonmyeloablative conditioning and
encourage further studies comparing immune recovery and immune
recovery mechanisms in pts given high-dose or nonmyeloablative
conditioning.194
EVIDENCE FOR QUANTITATIVE AND FUNCTIONAL IMMUNE DEVIATION
IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE
Kean, L.S.1, Sen, S.1, Felder, M.A.1, Tangpricha, V.1, Adisa, O.1,
Herry, A.J.1, Buchanan, I.2, Ziegler, T.3, Alvarez, J.1, Beus, J.3,
Worthington-White, D.1, Robertson, J.3, George, J.4, Cetron, J.3,
Ofori-Acquah, S.F.1, Osunkwo, I.1 1Aflac Cancer Center and Blood
Disorders Service; 2Morehouse School of Medicine; 3Emory University;
4Sickle Cell Foundation of Georgia
While HSCT is a curative therapy for sickle cell disease (SCD),
SCD patients are at increased risk of graft rejection, especially afternon-myeloablative transplant. To determine whether immune
mechanisms might influence their increased risk of rejection, we
evaluated quantitative and functional immunologic differences be-
tween 23 pediatric SCD patients and 18 age- and ethnicity-matched
controls, using a prospective cross-sectional study design. All pa-
tients and controls were African American and were matched for
gender and age. All patients were at their clinical baseline during
evaluation: no patient was experiencing an acute complication of
SCD. Following informed consent, each subject underwent quanti-
tative flow cytometric immune analysis including enumeration of to-
tal WBC, ANC, ALC, total T cells, B cells and NK cells as well as
CD4+ and CD8+ naive and memory T cell subpopulations. Func-
tional immune assessment was also performed, using multiplexed
analysis of 25 serum cytokines.
Our results provide evidence for significant quantitative and func-
tional immune deviation in SCD patients compared to controls. In
addition to the well-documented increases in total WBC and ANC
(1.9-fold and 1.7-fold compared to controls, respectively, p\0.05),
SCD patients also demonstrated significantly higher total lympho-
cytes, monocytes and both cytotoxic and cytokine-secretingNK cells
(2.9, 2.4, and 2.2-fold compared to controls, p\0.01 for all). Circu-
lating B cells were significantly higher in SCD patients (3.3 fold, p5
0.0005). CirculatingT cells were also increased in SCDpatients, and
this effect was specific to CD4+ T cells (1.7-fold, p 5 0.002). There
was no difference in CD8+ T cells (p5 0.4). The increased CD4+ T
cell count predominantly involved memory CD4+ T subpopula-
tions, with both central and effector memory CD4+ T cells signifi-
cantly increased compared to controls (1.9-fold and 2.5-fold,
respectively, p\ 0.01). SCD patients also showed evidence of func-
tional immune activation at steady state; plasma cytokine analysis re-
vealed higher circulating CXCL10, CCL4 and IL-15 (2.4, 2.1, and
.10 fold compared to controls, p\0.05 for all).
Our results provide strong cellular and molecular evidence for
quantitative and functional immune deviation in SCD patients.
These observations suggest that strategies targeting NK cell, B
cell, and CD4T cell functionmay be required for successful engraft-
ment of SCD patients during non-myeloablative HSCT.
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SAFETY OF LIPOSOMAL CYTARABINE PROPHYLAXIS IN PEDIATRIC BONE
MARROWTRANSPLANT (BMT) RECIPIENTSWITH ACUTE LEUKEMIA (AL)
AND NON HODGKIN LYMPHOMA (NHL) AT HIGH RISK OF CNS RELAPSE
Hochberg, J., Duffy, D., Harrison, L., Morris, E., Cairo, M.S. New York
Medical College, Valhalla, NY
Liposomal Cytarabine (LC) is a derivative of cytarabine designed
for intrathecal treatment of leukemia/lymphomatous meningitis
(LLM). LC allows for sustained release with prolonged drug expo-
sure of 8 to 14 days in children and adults, respectively. Adult trials
have shown 50mg of LC to be both safe and effective in the treatment
of LLM (Glantz et al, JCO 1999). Bomgaars et al. investigated the
use of LC in children in a phase I dose escalation trial and demon-
strated the maximal tolerated dose to be 35mg and that it was safe,
well tolerated and effective (Bomgaars et al., JCO 2004). However,
there remains a paucity of data on the use of LC prophylaxis to pre-
vent LLM in pediatric allogeneic stem cell (AlloSCT) recipients.
Objective:We report on the safety and tolerability of liposomal cy-
tarabine prior to and following stem cell transplant in pediatric BMT
recipients with AL and NHL.
Methods:Pediatric stem cell recipients with a history of AL orNHL
and high risk of CNS disease received 35mg of LC (\21yr) or 50mg
(.21yr) via lumbar puncture or omaya reservoir pre conditioning
and every 3months for 1-2yrs post stem cell transplant. Patients re-
ceived dexamethasone (0.15mg/kg/dose BID) concomitantly x
5days. There were 8 matched unrelated donor transplants, 9
matched related donor transplants and 3 autologous transplants.
Twelve patients received a TBI (1200 cGy) containing conditioning
regimen. Seven patients received an additional CNS boost of up to
1200 cGy.
Results: To date there have been 21 patients: (12 ALL, 2 AML, 3
Burkitt, 3 DLBCL and 1 T-LL). At the time of transplant, 7 patients
were CR1/PR1, 10 patients CR2 and 4 patients CR3. Patients have
received a total of 46 doses (median 5 1, range 1-12). Median age:
12yr (range 6-22). Mean follow up: 517 days (median 5 294days).
Eight of 21 patients had a history of CNS AL/NHL involvement
S276 Poster Session Iprior to AlloSCT but none with evidence of LLM at the time of
AlloSCT. Two patients experienced Grade II-III headache. Grade
II-III vomiting was also noted in 2 additional patients. Seven patients
developed relapsed systemic disease but none of them had CNS AL/
NHL at time of death.
Conclusion: These preliminary results suggest that prophylactic li-
posomal cytarabine is tolerable and effective in pediatric AlloSCT
and AutoSCT recipients at risk for CNS relapse. Larger studies
are needed in the future to compare this to other CNS prophylaxis
regimens post auto or AlloSCT.
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G-CSF MOBILIZATION ALONE, A SHORTER DURATION OF NEUTROPENIA,
AND THE RAPIDITY OF ENGRAFTMENT ARE ASSOCIATED WITH EN-
GRAFTMENT SYNDROME IN PATIENTS UNDERGOING AUTOLOGOUS
PBSCT FOR MULTIPLE MYELOMA
Burnette, B.1, Dispenzieri, A.1, Porrata, L.1, Hogan, W.1, Holtan, S.2
1Mayo Clinic Foundation, Rochester, MN; 2Oregon Health Sciences Uni-
versity, Portland, OR
Introduction: Maiolino in 2003 proposed criteria for Engraftment
Syndrome (ES). Criteria included non infectious fever plus one (or
more) of the following: rash, pulmonary infiltrates, or diarrhea. Clin-
ical practice has since shifted. In the Maiolino series all patients were
mobilized with cyclophosphamide (CTX) andG-CSF, while current
options include G-CSF, G-CSF plus plerixafor, or CTX with
G-CSF. Patients were also treated with G-CSF in the early trans-
plant period. We felt it appropriate to assess our experience with
ES in modern patients with multiple myeloma.
Methods: After IRB approval, the Mayo Clinic BMT Database was
queried for all patients between 1/1/2009 and 12/31/2009 whom un-
derwent autologous PBSCT for multiple myeloma. Patient records
were accessed to assess the rate of non-infectious fever, engraftment
syndrome, time to engraftment, rapidity of engraftment, mobiliza-
tion regimens, and demographic information. Criteria for ES in-
cluded non-infectious fever occurring up to 5 days prior to
ANC.500 plus rash, diarrhea or significant worsening of prior diar-
rhea, or pulmonary decline (defined as new oxygen requirement, in-
creased oxygen requirement, pulmonary infiltrates, or new
tachypnea .20).
Results: 112 patients were identified. All patients received G-CSF
for mobilization. 51 (46%) received G-CSF alone, 45 (40%) with
CTX (1.5 gm/m2 daily for two days), 23 (20%) with plerixafor, 3
(2.6%) with both G-CSF and CTX, and one during recovery from
chemotherapy (VDT-PACE). Two patient received G-CSF in the
early transplant period on a clinical trial. Eighteen patients (16%)
met our criteria for ES. The relative risk of conditioning with G-
CSF alone was 3.1 (95% CI 1.1-9.6). Median time from WBC 500
to ANC 1000 was 3d (0-5) and 4d (0-14) with and without ES
(p 5 .004). Median duration of neutropenia was 8d (7-14) and 10d
(5-18) with and without ES (p 5 0.02). One patient with non-
infectious fever and increased oxygen requirement experienced sud-
den death soon after hospital admission onD+8, felt to be potentially
attributable to ES.
Discussion: Our data confirm a similar incidence of ES as that de-
scribed by Maiolino. For the first time, we have also demonstrated
an association between G-CSF mobilization alone, rapidity of en-
graftment, and duration of neutropenia with the clinical diagnosis
of ES. It is speculated that the composition of the autologous stem
cell product may differ with mobilization regimens currently utilized
in clinical practice.
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DOUBLE CORD BLOOD TRANSPLANTATION: PRE-ENGRAFTMENT OR
RECESSIVE CORD REJECTION SYNDROME?
El Amil, Z.G.1, L’Heureux, J.1, Welch, P.1, Roy, T.1, Tuncer, H.H.1,2,
Al-Homsi, A.S.1,2 1Roger Williams Medical Center, Providence, RI;
2Boston University School of Medicine, Boston, MA
Pre-engraftment syndrome (PES) is a mechanistically poorly
understood clinical syndrome essentially characterized by fever and
erythematous skin rash with no infectious process and which occurs
shortly before neutrophil recovery after double cord blood trans-
plantation. The syndrome promptly responds to small doses of ste-
roids. Similar clinical syndrome has been described with rejectionof mismatched hematopoietic stem cells. Herein, we provide prelim-
inary post-chimerism data suggesting that the syndrome is concom-
itant with the disappearance of one of the two infused cords and
possibly indeed due to the rejection of one of the cords as opposed
to engraftment.
Three patients underwent double cord blood transplantation us-
ing a conditioning regimen combining cyclophosphamide, fludara-
bine and total body irradiation for primary myelofibrosis, acute
myeloid leukemia and chronic myeloid leukemia in blast crisis.
Patients 1 and 3 received myeloabaltive conditioning while patient
2 received non-myeloablative treatment. All three patients showed
unexplained fever and erythematous skin rash on days +13, +20,
and +12 respectively. All three patients rapidly responded to small
doses of steroids. Post-chimerism studies on the first patient on
day +12 showed 46% non patient DNA with both cords equally rep-
resented. A repeat study on day +19 showed 56% non patient DNA
with only one cord detected. Post-chimerism studies on the second
patient on day +22, when the clinical syndrome was present, showed
86% non patient DNA with both cords present while the same
studies done on the third patient on day +17 after resolution of the
syndrome showed only non patient DNA derived from one cord.
In summary, we showed some preliminary post-chimerism studies
on patients with double cord blood transplantation with PES sug-
gesting that the syndrome rather corresponds to rejection of one
of the cords. The data is supported by the fact that the syndrome
was described after double cord transplants and the similarity of
the syndrome with the rejection syndrome observed after infusion
of mismatched hematopoietic stem cells. Therefore, we suggest fur-
ther studies to elucidate the mechanism of the syndrome and suggest
rather the name of recessive cord rejection syndrome or RCRS.
198
COMPARISION OF THE IMMUNE RECONSTITUTION IN CHILDREN TRANS-
PLANTED WITH 3 DIFFERENT TYPES OF HEMATOPOIETIC STEM CELLS,
EXPERIENCE OF THE NATIONAL INSTITUTE OF PEDIATRICS MEXICO
Perez-Garcia, M.1, Olaya-Vargas, A.1, Del Campo-Martinez, A.1,
Juarez-Nicolas, F.2, Mujica-Guzman, F.2, Lopez-Hernandez, G.1,
Castorena-Villa, I.1 1National Pediatric Institute, Mexico, DF, Mexico;
2National Pediatric Institute, Mexico, DF, Mexico
Introduction:The aim of hematopoietic progenitor cell transplants
(HPCT) is to implant a healthy system in the place of an unhealthy
one. Total immunological recovery is a slow process and often after
the transplant remains incomplete. Although the reconstitution of
innate immunity is fast, adaptive immunity is seen to be compro-
mised for years, especially in lymphopoiesis of B and T cells. Present
study compare the immune recontitution in pediatric patients post-
transplanted with 3 different types of hematopoietic progenitor cells
from 2008 – 2010. In the National Institute of Pediatrics, Mexico.
Materials and Method: 31 patients (12 females and 19 males) who
were subjected to hematopoietic progenitor cell transplants in bone
marrow transplantation unit in Pediatrics National Institute (INP)
were recruited for the study. The study is retrospective. Autologous
transplant was carried out in 2 of the patients while allogenic trans-
plant was done in 29 of them. According to our data source, 14 of the
transplants were with umbilical cord cells and 17 with peripheral
blood. Subpopulation post-transplant follow-up was carried out by
means of flow cytometry using surface monoclonal antibodies:
CD3, CD4, CD8, CD19, and CD56 for 3, 6, 9, and 12 months.
Results: All the patients showed similar tendency. It was observed
that cells with CD3 immunophenotype presented normal values
from the beginning at the expense of adequate values of CD8, while
the values of CD4 remained low all through the follow-up. There is
significant statistical difference between the numbers of CD3 in pe-
ripheral blood compared with that of the umbilical cord at 3 months.
CD4/CD8 index was found with normal values from the beginning
and throughout the follow-up while the absolute values of CD19 and
CD56 cell immunophenotypes were found below normal in all the
detections.
Conclusion: From the data obtained in the lymphocyte sub-popula-
tionsmeasurement, incomplete immunological reconstitution at one
year was observed not only in peripheral blood but also in umbilical
cord. However, we suggest that further studies involving higher
number of cases is need to establish a definitive reconstitution
pattern.
